Registro:

Referencias:

• Luder, C.G.K., Bohne, W., Soldati, D., Toxoplasmosis: A persisting challenge (2001) Trends in Parasitology, 17 (10), pp. 460-463. , DOI 10.1016/S1471-4922(01)02093-1, PII S1471492201020931
• Innes, E.A., A brief history and overview of toxoplasma gondii (2010) Zoonoses Public Health, 57, pp. 1-7
• Frenkel, J.K., Remington, J.S., Wong, S.-Y., Prevention of toxoplasma infection in pregnant women and their fetuses (1995) Clin. Infect. Dis., 20, pp. 727-729
• Tenter, A.M., Heckerost, A.R., Weiss, L.M., Toxoplasma gondii: From animals to humans (2000) Int. J. Parasitol., 30, pp. 1217-1258
• Moreno, S.N.J., Li, Z.-H., Targeting the isoprenoid pathway of Toxoplasma gondii (2008) Expert Opinion on Therapeutic Targets, 12 (3), pp. 253-263. , DOI 10.1517/14728222.12.3.253
• Glatt, A.E., Chirgwin, K., Landesman, S.H., Treatment of infections associated with human immunodeficiency virus (1988) N. Engl. J. Med., 318, pp. 1439-1448
• Yolken, R.H., Bachmann, S., Rouslanova, I., Lillehoj, E., Ford, G., Torrey, E.F., Schroeder, J., Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia (2001) Clinical Infectious Diseases, 32 (5), pp. 842-844. , DOI 10.1086/319221
• Nicolle, C., Manceaux sur une infection A corps de leishman (ou organism voisin) du gondi (1908) C R Hebd. Seances Acad. Sci., 147, pp. 763-766
• Levine, N.D., Corliss, J.O., Cox, F.E., A newly revised classification of the protozoa (1980) J. Protozool., 27, pp. 37-58
• Carruthers, V., Boothroyd, J.C., Pulling together: an integrated model of Toxoplasma cell invasion (2007) Current Opinion in Microbiology, 10 (1), pp. 83-89. , DOI 10.1016/j.mib.2006.06.017, PII S1369527406001007
• Fichera, M.E., Roos, D.S., A plastid organelle as a drug target in apicomplexan parasites (1997) Nature, 390 (6658), pp. 407-409. , DOI 10.1038/37132
• Stokkermans, T.J.W., Schwartzman, J.D., Keenan, K., Morrissette, N.S., Tilney, L.G., Roos, D.S., Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides (1996) Experimental Parasitology, 84 (3), pp. 355-370. , DOI 10.1006/expr.1996.0124
• Roberts, F., Roberts, C.W., Johnson, J.J., Kyle, D.E., Krell, T., Coggins, J.R., Coombs, G.H., McLeod, R., Evidence for the shikimate pathway in apicomplexan parasites (1998) Nature, 393 (6687), pp. 801-805. , DOI 10.1038/31723
• Dubey, J.P., Lindsay, D.S., Speer, C.A., Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts (1998) Clinical Microbiology Reviews, 11 (2), pp. 267-299
• Georgiev, V.St., Management of toxoplasmosis (1994) Drugs, 48 (2), pp. 179-188
• Moreno, S.N.J., Docampo, R., Calcium regulation in protozoan parasites (2003) Current Opinion in Microbiology, 6 (4), pp. 359-364. , DOI 10.1016/S1369-5274(03)00091-2
• Sabin, A.B., Warren, J., Therapeutic effect of the sulfonamides on the infection with intracellular protozoa (toxoplasma (1941) J. Bacteriol., 41, pp. 80-86
• Eyles, D.E., Coleman, N., Synergistic effect of sulfadiazine and daraprim against toxoplasmosis in mice (1953) Antibiot. Chemother., 3, pp. 483-490
• Beverly, J.K.A., A rational approach to the treatment of toxoplasma uveitis (1958) Trans. Ophtalmol. Soc. UK, 78, pp. 109-121
• Chang, H.R., Pechere, J.-C.F., Effect of roxithromycin or acute toxoplasmosis in mice (1987) Antimicrobial Agents and Chemotherapy, 31 (7), pp. 1147-1149
• Chang, H.R., Pechere, J.-C.F., In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii (1988) Antimicrobial Agents and Chemotherapy, 32 (4), pp. 524-529
• Garin, J.P., Eyles, D.E., Le traitement de la toxoplasmose experimentale de la souris par la spiramycine (1958) Press. Med., 66, pp. 957-958
• Desmonts, G., Couvreur, J., Congenital toxoplasmosis a prospective study of 378 pregnancies (1974) N. Engl. J. Med., 290, pp. 1110-1116
• Baggish, A.L., Hill, D.R., Antiparasitic agent atovaquone (2002) Antimicrobial Agents and Chemotherapy, 46 (5), pp. 1163-1173. , DOI 10.1128/AAC.46.5.1163-1173.2002
• Sun, I.L., Sun, E.E., Crane, F.L., Requirement for coenzyme Q in plasma membrane electron transport (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11126-30
• McFadden, D.C., Tomavo, S., Berry, E.A., Boothroyd, J.C., Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance (2000) Molecular and Biochemical Parasitology, 108 (1), pp. 1-12. , DOI 10.1016/S0166-6851(00)00184-5, PII S0166685100001845
• Harris, C., Salgo, M.P., Tanowitz, H.B., Wittner, M., In vitro assessment of antimicrobial agents against Toxoplasma gondii (1988) Journal of Infectious Diseases, 157 (1), pp. 14-22
• Rytel, M.W., Jones, T.C., Introduction of interferon in mice infected with Toxoplasma gondii (1966) Proc. Soc. Exp. Biol. Med., 123, pp. 859-862
• Koo, L., Young, L.H., Management of ocular toxoplasmosis (2006) International Ophthalmology Clinics, 46 (2), pp. 183-193. , PII 0000439720060462000015
• Avery, M.A., Alvim-Gaston, M., Vroman, J.A., Wu, B., Ager, A., Peters, W., Robinson, B.L., Charman, W., Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates (2002) Journal of Medicinal Chemistry, 45 (19), pp. 4321-4335. , DOI 10.1021/jm020142z
• Vroman, J.A., Alvim-Gaston, M., Avery, M.A., Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials (1999) Current Pharmaceutical Design, 5 (2), pp. 101-138
• Ou-Yang, K., Krug, E.C., Marr, J.J., Berens, R.L., Inhibition of growth of Toxoplasma gondii by Qinghaosu and derivatives (1990) Antimicrobial Agents and Chemotherapy, 34 (10), pp. 1961-1965
• Chang, H.R., Pechere, J.-C., Arteether,a qinghaosu derivative in toxoplasmosis (1988) Trans. R Soc. Trop. Med. Hyg., 82, p. 867
• Jones-Brando, L., D'Angelo, J., Posner, G.H., Yolken, R., In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin (2006) Antimicrobial Agents and Chemotherapy, 50 (12), pp. 4206-4208. , DOI 10.1128/AAC.00793-06
• D'Angelo, J.G., Bordon, C., Posner, G.H., Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle (2009) J. Antimicrob Chemother, 63, pp. 146-150
• Brando, L.V., Posner, G.H., D'Angelo, J.G., Artemisinin derivatives (2008) WO2008127381A2
• Hencken, C.P., Jones-Brando, L., Bordon, C., Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii (2010) J. Med. Chem., 53, pp. 3594-601
• Posner, G.H., Endoperoxidases useful as antiparasitic agents (1998) US5817962
• Haynes, R.K., Fugmann, B., Stetter, J., Rieckmann, K., Heilmann, H.-D., Chan, H.-W., Cheung, M.-K., Romer, A., Artemisone - A highly active antimalarial drug of the artemisinin class (2006) Angewandte Chemie - International Edition, 45 (13), pp. 2082-2088. , DOI 10.1002/anie.200503071
• Schmeer, K., Wollborn, U., Antiparasitic artemisinin derivatives (2006) EP1714967A1
• Posner, G.H., Woodard, L.E., Levine, D.R., Tioxane monomers and dimmers (2010) WO2010135427
• Woodard, L.E., Chang, W., Chen, X., Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose (2009) J. Med. Chem., 52, pp. 7458-7462
• Nagamune, K., Beatty, W.L., Sibley, L.D., Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii (2007) Eukaryotic Cell, 6 (11), pp. 2147-2156. , DOI 10.1128/EC.00262-07
• Nagamune, K., Moreno, S.N.J., Sibley, L.D., Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis (2007) Antimicrobial Agents and Chemotherapy, 51 (11), pp. 3816-3823. , DOI 10.1128/AAC.00582-07
• Kawase, O., Nishikawa, Y., Bannai, H., Zhang, H., Zhang, G., Jin, S., Lee, E.-G., Xuan, X., Proteomic analysis of calcium-dependent secretion in Toxoplasma gondii (2007) Proteomics, 7 (20), pp. 3718-3725. , DOI 10.1002/pmic.200700362
• O'Neill, P.M., Rawe, S.L., Borstnik, K., Miller, A., Ward, S.A., Bray, P.G., Davies, J., Posner, G.H., Enantiomeric 1,2,4-trioxanes display equivalent in vitro antimalarial activity versus Plasmodium falciparum malaria parasites: Implications for the molecular mechanism of action of the artemisinins (2005) ChemBioChem, 6 (11), pp. 2048-2054. , DOI 10.1002/cbic.200500048
• O'Neill, P.M., Posner, G.H., A medicinal chemistry perspective on artemisinin and related endoperoxides (2004) Journal of Medicinal Chemistry, 47 (12), pp. 2945-2964. , DOI 10.1021/jm030571c
• Urbina, J.A., Parasitological Cure of Chagas Disease: Is it Possible? Is it Relevant? (1999) Memorias do Instituto Oswaldo Cruz, 94 (SUPPL. 1), pp. 349-355
• Docampo, R., Moreno, S.N., Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites (2001) Curr. Drug Targets Infect. Disord, 1, pp. 51-61
• Docampo, R., Moreno, S.N.J., The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites (2008) Current Pharmaceutical Design, 14 (9), pp. 882-888. , http://www.ingentaconnect.com/content/ben/cpd/2008/00000014/00000009/ art00007, DOI 10.2174/138161208784041079
• Gelb, M.H., Van Voorhis, W.C., Buckner, F.S., Yokoyama, K., Eastman, R., Carpenter, E.P., Panethymitaki, C., Smith, D.F., Protein farnesyl and N-myristoyl transferases: Piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics (2003) Molecular and Biochemical Parasitology, 126 (2), pp. 155-163. , DOI 10.1016/S0166-6851(02)00282-7, PII S0166685102002827
• Eberl, M., Hintz, M., Reichenberg, A., Kollas, A.-K., Wiesner, J., Jomaa, H., Microbial isoprenoid biosynthesis and human γδ T cell activation (2003) FEBS Letters, 544 (1-3), pp. 4-10. , DOI 10.1016/S0014-5793(03)00483-6
• Garcia Linares, G., Ravaschino, E.L., Rodriguez, J.B., Progresses in the field of drug design to combat tropical protozoan Parasitic diseases (2006) Curr. Med. Chem., 13, pp. 335-360
• Dantas-Leite, L., Urbina, J.A., De Souza, W., Vommaro, R.C., Selective anti-Toxoplasma gondii activities of azasterols (2004) International Journal of Antimicrobial Agents, 23 (6), pp. 620-626. , DOI 10.1016/j.ijantimicag.2003.11.005, PII S0924857904000457
• Urbina, J.A., Vivas, J., Lazardi, K., Antiproliferative effects of Delta24(25) sterol methyl transferase inhibitors on trypanosoma (schizotrypanum) cruzi: In vitro and in vivo studies (1996) Chemotherapy, 42, pp. 294-307
• Rodrigues, J.C.F., Attias, M., Rodriguez, C., Urbina, J.A., De Souza, W., Ultrastructural and biochemical alterations induced by 22,26-azasterol, a Δ 24(25)-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis (2002) Antimicrobial Agents and Chemotherapy, 46 (2), pp. 487-499. , DOI 10.1128/AAC.46.2.487-499.2002
• Urbina, J.A., Visbal, G., Contreras, L.M., McLaughlin, G., Docampo, R., Inhibitors of Δ(24(25)) sterol methyltransferase block sterol synthesis and cell proliferation in Pneumocystis carinii (1997) Antimicrobial Agents and Chemotherapy, 41 (7), pp. 1428-1432
• Dantas-Leite, L., Urbina, J.A., Souza, W.D., Vommaro, R.C., Antiproliferative synergism of azasterols and antifolates against Toxoplasma gondii (2005) International Journal of Antimicrobial Agents, 25 (2), pp. 130-135. , DOI 10.1016/j.ijantimicag.2004.08.016, PII S0924857904003887
• Roelofs, A.J., Thompson, K., Ebetino, F.H., Bisphosphonates: Molecular mechanisms of action and effects on bone cells, monocytes and macrophages (2010) Curr. Pharm. Des., 16, pp. 2950-2960
• Reszka, A.A., Rodan, G.A., Nitrogen-containing bisphosphonate mechanism of action (2004) Mini. Rev. Med. Chem., 4, pp. 711-717
• Reszka, A.A., Rodan, G.A., Mechanism of action of bisphosphonates (2003) Curr. Osteoporos. Rep., 1, pp. 45-52
• Fleisch, H., Russell, R.G.G., Straumann, F., Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis (1966) Nature, 212, pp. 901-903
• Fleisch, H., Russell, R.G.G., Francis, M.D., Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo (1969) Science, 165, pp. 1262-264
• Francis, M.D., Russell, R.G.G., Fleisch, H., Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo (1969) Science, 165, pp. 1264-266
• Urbina, J.A., Moreno, B., Vierkotter, S., Oldfield, E., Payares, G., Sanoja, C., Bailey, B.N., Docampo, R., Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs (1999) Journal of Biological Chemistry, 274 (47), pp. 33609-33615
• Hughes, D.E., Wright, K.R., Uy, H.L., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo (1995) J. Bone Miner. Res., 10, pp. 1478-1487
• Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Monkkonen, J., Auriola, S., Russell, R.G.G., Molecular mechanisms of action of bisphosphonates (1999) Bone, 24 (SUPPL.), pp. 73S-79S. , DOI 10.1016/S8756-3282(99)00070-8, PII S8756328299000708
• KaVanagh, K.L., Guo, K., Dunford, J.E., The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs (2006) Proc. Natl. Acad. Sci., 103, pp. 7829-7834
• Hosfield, D.J., Zhang, Y., Dougan, D.R., Broun, A., Tari, L.W., Swanson, R.V., Finn, J., Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis (2004) Journal of Biological Chemistry, 279 (10), pp. 8526-8529. , DOI 10.1074/jbc.C300511200
• Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D., Ebetino, F.H., Rogers, M.J., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates (2001) Journal of Pharmacology and Experimental Therapeutics, 296 (2), pp. 235-242
• Coxon, F.P., Thompson, K., Rogers, M.J., Recent advances in understanding the mechanism of action of bisphosphonates (2006) Current Opinion in Pharmacology, 6 (3), pp. 307-312. , DOI 10.1016/j.coph.2006.03.005, PII S1471489206000610, Respiratory/Musculoskeletal
• Reddy, R., Dietrich, E., Lafontaine, Y., Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis (2008) Chem. Med. Chem., 3, pp. 1863-868
• Clezardin, P., Massaia, M., Nitrogen-containing bisphosphonates and cancer immunotherapy (2010) Curr. Pharm. Des., 16, pp. 3007-3014
• Miller, K., Erez, R., Segal, E.., Targeting bone metastases with bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate (2009) Angew. Chem. Int. Ed., 48, pp. 2949-2954
• Coleman, R.E., Risks and benefits of bisphosphonates (2008) British Journal of Cancer, 98 (11), pp. 1736-1740. , DOI 10.1038/sj.bjc.6604382, PII 6604382
• Roth, A.G., Drescher, D., Yang, Y., Potent and selective inhibition of acid sphingomyelinase by bisphosphonates (2009) Angew. Chem. Int. Ed., 48, pp. 7560-563
• Ghosh, S., Chan, J.M.W., Lea, C.R., Meints, G.A., Lewis, J.C., Tovian, Z.S., Flessner, R.M., Oldfield, E., Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo (2004) Journal of Medicinal Chemistry, 47 (1), pp. 175-187. , DOI 10.1021/jm030084x
• Martin, M.B., Grimley, J.S., Lewis, J.C., Heath III, H.T., Bailey, B.N., Kendrick, H., Yardley, V., Oldfield, E., Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy (2001) Journal of Medicinal Chemistry, 44 (6), pp. 909-916. , DOI 10.1021/jm0002578
• Yardley, V., Khan, A.A., Martin, M.B., Slifer, T.R., Araujo, F.G., Moreno, S.N.J., Docampo, R., Oldfield, E., In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii (2002) Antimicrobial Agents and Chemotherapy, 46 (3), pp. 929-931. , DOI 10.1128/AAC.46.3.929-931.2002
• Martin, M.B., Sanders, J.M., Kendrick, H., De Luca-Fradley, K., Lewis, J.C., Grimley, J.S., Van Brussel, E.M., Oldfield, E., Activity of bisphosphonates against Trypanosoma brucei rhodesiense (2002) Journal of Medicinal Chemistry, 45 (14), pp. 2904-2914. , DOI 10.1021/jm0102809
• Rosso, V.S., Szajnman, S.H., Malayil, L., Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1- bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase (2011) Bioorg. Med. Chem., 19, pp. 2211-2217
• Szajnman, S.H., Garcia Linares, G.E., Li, Z.-H., Jiang, C., Galizzi, M., Bontempi, E.J., Ferella, M., Rodriguez, J.B., Synthesis and biological evaluation of 2-alkylaminoethyl-1,1- bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase (2008) Bioorganic and Medicinal Chemistry, 16 (6), pp. 3283-3290. , DOI 10.1016/j.bmc.2007.12.010, PII S0968089607010607
• Szajnman, S.H., Bailey, B.N., Docampo, R., Rodriguez, J.B., Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi (2001) Bioorganic and Medicinal Chemistry Letters, 11 (6), pp. 789-792. , DOI 10.1016/S0960-894X(01)00057-9, PII S0960894X01000579
• Szajnman, S.H., Montalvetti, A., Wang, Y., Docampo, R., Rodriguez, J.B., Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase (2003) Bioorganic and Medicinal Chemistry Letters, 13 (19), pp. 3231-3235. , DOI 10.1016/S0960-894X(03)00663-2
• Szajnman, S.H., Ravaschino, E.L., Docampo, R., Rodriguez, J.B., Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase (2005) Bioorganic and Medicinal Chemistry Letters, 15 (21), pp. 4685-4690. , DOI 10.1016/j.bmcl.2005.07.060, PII S0960894X05009698
• Ling, Y., Sahota, G., Odeh, S., Chan, J.M.W., Araujo, F.G., Moreno, S.N.J., Oldfield, E., Bisphosphonate inhibitors of Toxoplasma gondi growth: In vitro, QSAR, and in vivo investigations (2005) Journal of Medicinal Chemistry, 48 (9), pp. 3130-3140. , DOI 10.1021/jm040132t
• Ling, Y., Li, Z.-H., Miranda, K., Oldfield, E., Moreno, S.N.J., The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates (2007) Journal of Biological Chemistry, 282 (42), pp. 30804-30816. , http://www.jbc.org/cgi/reprint/282/42/30804, DOI 10.1074/jbc.M703178200
• Szajnman, S.H., Rosso, V.S., Malayil, L., Design, synthesis and biological evaluation of 1-(fluoroalkylidene)-1,1- bisphosphonic acids against toxoplasma gondii targeting farnesyl diphosphate synthase (2012) Org. Biomol. Chem., (10), pp. 1424-1433
• Jeanmougin, F., Thompson, J.D., Gouy, M., Higgins, D.G., Gibson, T.J., Multiple sequence alignment with Clustal X (1998) Trends in Biochemical Sciences, 23 (10), pp. 403-405. , DOI 10.1016/S0968-0004(98)01285-7, PII S0968000498012857
• Cinque, G.M., Szajnman, S.H., Zhong, L., Docampo, R., Schvartzapel, A.J., Rodriguez, J.B., Gros, E.G., Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi (1998) Journal of Medicinal Chemistry, 41 (9), pp. 1540-1554. , DOI 10.1021/jm970860z
• Szajnman, S.H., Yan, W., Bailey, B.N., Docampo, R., Elhalem, E., Rodriguez, J.B., Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation (2000) Journal of Medicinal Chemistry, 43 (9), pp. 1826-1840. , DOI 10.1021/jm9905007
• Elhalem, E., Bailey, B.N., Docampo, R., Ujvary, I., Szajnman, S.H., Rodriguez, J.B., Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi (2002) Journal of Medicinal Chemistry, 45 (18), pp. 3984-3999. , DOI 10.1021/jm0201518
• Urbina, J.A., Concepcion, J.L., Montalvetti, A., Rodriguez, J.B., Docampo, R., Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease (2003) Antimicrobial Agents and Chemotherapy, 47 (6), pp. 2047-2050. , DOI 10.1128/AAC.47.6.2047-2050.2003
• Martins-Duarte, E.S., Urbina, J.A., De Souza, W., Vommaro, R.C., Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro (2006) Journal of Antimicrobial Chemotherapy, 58 (1), pp. 59-65. , DOI 10.1093/jac/dkl180
• Linares, G.G., Gismondi, S., Codesido, N.O., Moreno, S.N.J., Docampo, R., Rodriguez, J.B., Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation (2007) Bioorganic and Medicinal Chemistry Letters, 17 (18), pp. 5068-5071. , DOI 10.1016/j.bmcl.2007.07.012, PII S0960894X07008141
• Blaney, J.M., Hansch, C., Silipo, C., Vittoria, A., Structure-activity relationships of dihydrofolate reductase inhibitors (1984) Chemical Reviews, 84 (4), pp. 333-407. , DOI 10.1021/cr00062a002
• Zuccotto, F., Martin, A.C.R., Laskowski, R.A., Thornton, J.M., Gilbert, I.H., Dihydrofolate reductase: A potential drug target in trypanosomes and leishmania (1998) Journal of Computer-Aided Molecular Design, 12 (3), pp. 241-257
• Gangjee, A., Lin, X., Queener, S.F., Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6- substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors (2004) Journal of Medicinal Chemistry, 47 (14), pp. 3689-3692. , DOI 10.1021/jm0306327
• Rosowsky, A., Forsch, R.A., 2,4-diamino-5- [5'-substituted-benzyl] pyrimidines and 2,4-diamino-6-[5'-substituted-benzyl] quinazolines (2004) WO2004082613A2
• Rosowsky, A., Forsch, R.A., Sibley, C.H., Inderlied, C.B., Queener, S.F., New 2,4-Diamino-5-(2′,5′-substituted benzyl)pyrimidines as Potential Drugs against Opportunistic Infections of AIDS and Other Immune Disorders. Synthesis and Species-Dependent Antifolate Activity (2004) Journal of Medicinal Chemistry, 47 (6), pp. 1475-1486. , DOI 10.1021/jm030438k
• Rosowsky, A., Forsch, R.A., Queener, S.F., Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS (2003) Journal of Medicinal Chemistry, 46 (9), pp. 1726-1736. , DOI 10.1021/jm020466n
• Chan, D.C.M., Fu, H., Forsch, R.A., Queener, S.F., Rosowsky, A., Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with ω-carboxyalkoxy or ω-carboxy-1-alkynyl substitution in the side chain (2005) Journal of Medicinal Chemistry, 48 (13), pp. 4420-4431. , DOI 10.1021/jm0581718
• Popov, V.M., Yee, W.A., Anderson, A.C., Towards in silico lead optimization: Scores from ensembles of protein/ligand conformations reliably correlate with biological activity (2007) Proteins: Structure, Function and Genetics, 66 (2), pp. 375-387. , DOI 10.1002/prot.21201
• Anderson, A., Wright, D.L., Pelphrey, P.M., Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal antifungal and anticancer properties (2009) WO2009025919A2
• Pelphrey, P.M., Popov, V.M., Joska, T.M., Beierlein, J.M., Bolstad, E.S.D., Fillingham, Y.A., Wright, D.L., Anderson, A.C., Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis (2007) Journal of Medicinal Chemistry, 50 (5), pp. 940-950. , DOI 10.1021/jm061027h
• Gangjee, A., Qiu, Y., Li, W., Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: Classical and nonclassical 2-amino-4-oxo- 5-arylthio-substituted-6-methylthieno [2,3-d]pyrimidine antifolates (2008) J. Med. Chem., 51, pp. 5789-5797
• Johnson, E.F., Hinz, W., Atreya, C.E., Mechanistic characterization of Toxoplasma gondii thymidylate synthase (TS-DHFR)-dihydrofolate reductase (2002) J. Biol. Chem., 277, pp. 43126-36
• Gangjee, A., Li, W., Kisliuk, R.L., Design, syn thesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6- ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents (2009) J. Med. Chem., (52), pp. 4892-902
• Gangjee, A., Matherly, L.H., Selective proton coupled folate transporter and folate receptor and garftase inhibitor compounds and methods of using the same (2010) US20100081676A1
• Gangjee, A., Substituted pyrrolo[2,3-d] pyrimidines for selectively targeting tumor cells with FR type receptors (2011) US7981902 B2
• Deligny, M., Saidani, N., Bonneau, A.-L., Compounds with antiparasitic activity applications thereof to the treatment of infectious diseases caused by apicomplexans (2008) WO2008146172A2
• El Kouni, M.H., Adenosine metabolism in toxoplasma gondii: Potential targets for chemotherapy (2007) Curr. Pharm. Des., 13, pp. 581-597
• Krug, E.C., Marr, J.J., Berens, R.L., Purine metabolism in Toxoplasma gondii (1989) Journal of Biological Chemistry, 264 (18), pp. 10601-10607
• Schumacher, M.A., Scott, D.M., Mathews, I.I., Crystal structure of Toxoplasma gondii reveals a novel catalytic mechanism and prodrug binding (2000) J. Mol. Biol., 298, pp. 875-893
• Mathews, I.I., Erion, M.D., Ealick, S.E., Structure of human adenosine kinase at 1.5 A resolution (1998) Biochemistry, 37 (45), pp. 15607-15620. , DOI 10.1021/bi9815445
• Kim, Y.A., Sharon, A., Chu, C.K., Rais, R.H., Al Safarjalani, O.N., Naguib, F.N.M., Kouni, M.H., Synthesis, biological evaluation and molecular modeling studies of N 6-benzyladenosine analogues as potential anti-toxoplasma agents (2007) Biochemical Pharmacology, 73 (10), pp. 1558-1572. , DOI 10.1016/j.bcp.2007.01.026, PII S0006295207000330
• Young, A.K., Sharon, A., Chu, C.K., Rais, R.H., Al Safarjalani, O.N., Naguib, F.N.M., El Kouni, M.H., Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase (2008) Journal of Medicinal Chemistry, 51 (13), pp. 3934-3945. , DOI 10.1021/jm800201s
• Al Safarjalani, O.N., Rais, R.H., Kim, Y.A., 7-Deaza-6-benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: Activities and selective toxicities (2008) Biochem. Pharmacol., 76, pp. 958-966
• Al Safarjalani, O.N., Rais, R.H., Kim, Y.A., Carbocyclic 6-benzylthioinosine analogues as subversive substrates of toxoplasma gondii adenosine kinase: Biological activities and selective toxicities (2010) Biochem. Pharmacol., 80, pp. 955-963
• Kim, Y.A., Rawal, R.K., Yoo, J., Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of toxoplasma gondii adenosine kinase (2010) Bioorg. Med. Chem., 18, pp. 3403-3412
• El Kouni, M.H., Guarcello, V., Naguib, F.N.M., Treatment of toxoplasmosis (1998) US5773424
• Fichera, M.E., Roos, D.S., A plastid organelle as a drug target in apicomplexan parasites (1997) Nature, 390 (6658), pp. 407-409. , DOI 10.1038/37132
• Baird, J.K., Drugs therapy: Effectiveness of antimalarial drugs (2005) N. Engl. J. Med., 352, pp. 1565-1577
• Pfefferkorn, E.R., Borotz, S.E., Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin (1994) Antimicrobial Agents and Chemotherapy, 38 (1), pp. 31-37
• Araujo, F.G., Shepard, R.M., Remington, J.S., In vivo activity of the macrolide antibiotics azithromycin, roxithromycin, ans spiramycin against Toxoplasma gondii (1991) Eur. J. Clin. Microbiol., 10, pp. 519-524
• Lee, Y., Choi, J.Y., Fu, H., Chemistry and biology of macrolide antiparasitic agents (2011) J. Med. Chem., 54, pp. 2792-804
• Fichera, M.E., Bophale, M.K., Roos, D.S., In vitro assays elucidate peculiar kinetics of clindamycin action against toxoplasma gondii (1995) Antimicrob Agents Chemother, 39, pp. 1530-1537
• Bell, A., Monaghan, P., Page, A.P., Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action (2006) International Journal for Parasitology, 36 (3), pp. 261-276. , DOI 10.1016/j.ijpara.2005.11.003, PII S0020751905003905
• Adams, B., Musiyenko, A., Kumar, R., Barik, S., A novel class of dual-family immunophilins (2005) Journal of Biological Chemistry, 280 (26), pp. 24308-24314. , DOI 10.1074/jbc.M500990200
• Remington, J.S., Araujo, F.G., Treatment for toxoplasmosis with a composition comprising a macrolide antibiotic and a spiropiperidyl derivative of rifamycin S (1997) US5648345
• Darkin-Rattray, S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley, T.M., Allocco, J.J., Cannova, C., Schmatz, D.M., Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase (1996) Proceedings of the National Academy of Sciences of the United States of America, 93 (23), pp. 13143-13147. , DOI 10.1073/pnas.93.23.13143
• Gissot, M., Kelly, K.A., Ajioka, J.W., Epigenomic modifications predict active promoters and gene structure in toxoplasma gondii (2007) PLoS Pathog., 3, pp. e77
• Saksouk, N., Bhatti, M.M., Kieffer, S., Smith, A.T., Musset, K., Garin, J., SulliVan Jr., W.J., Hakimi, M.-A., Histone-modifying complexes regulate gene expression pertinent to the differentiation of the protozoan parasite Toxoplasma gondii (2005) Molecular and Cellular Biology, 25 (23), pp. 10301-10314. , DOI 10.1128/MCB.25.23.10301-10314.2005
• Singh, S.B., Zink, D.L., Polishook, J.D., Dombrowski, A.W., Darkin-Rattray, S.J., Schmatz, D.M., Goetz, M.A., Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum (1996) Tetrahedron Letters, 37 (45), pp. 8077-8080. , DOI 10.1016/0040-4039(96)01844-8, PII S0040403996018448
• Meinke, P.T., Liberator, P., Histone deacetylase: A target for antiproliferative and antiprotozoal agents (2001) Current Medicinal Chemistry, 8 (2), pp. 211-235
• Singh, S.B., Zink, D.L., Liesch, J.M., Mosley, R.T., Dombrowski, A.W., Bills, G.F., Darkin-Rattray, S.J., Goetz, M.A., Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities (2002) Journal of Organic Chemistry, 67 (3), pp. 815-825. , DOI 10.1021/jo016088w
• Singh, S.B., Zink, D.L., Liesch, J.M., Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with praline and valine substitutions (2011) Org. Lett., 3, pp. 2815-2818
• Cannova, C.L., Dambrowski, A.W., Goetz, M.A., Antiprotozoal cyclic tetrapeptides (1999) US5861375
• Meinke, P.T., Schmatz, D., Fisher, M.H., (2001) Apicidin-Derived Cyclic Tetrapeptides, , WO0107042A1;
• Liesch, J.M., Sweeley, C.C., Staffeld, G.D., Structure of HC-toxin, a cyclic tetrapeptide from Helminthosporium carbonum (1982) Tetrahedron, 38 (1), pp. 45-48. , DOI 10.1016/0040-4020(82)85043-6
• Mori, H., Urano, Y., Abe, F., Furukawa, S., Furukawa, S., Tsurumi, Y., Sakamoto, K., Fujii, T., FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities (2003) Journal of Antibiotics, 56 (2), pp. 72-79
• Xie, W., Zou, B., Pei, D., Ma, D., Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases (2005) Organic Letters, 7 (13), pp. 2775-2777. , DOI 10.1021/ol050991r
• Bougdour, A., Maubon, D., Baldacci, P., Drug inhibition of HDAC3 and epigenetic control of differentiation in apicomplexa parasites (2009) J. Exp. Med., 206, pp. 953-966
• Maubon, D., Bougdour, A., Wong, Y.-S., Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: Inhibition of stage conversion of the parasite cyst form and study of new derivative compounds (2010) Antimicrob Agents Chemother, 54, pp. 4843-4850
• Wong, Y.-S., Hakimi, M.-A., Bougdour, A., (2010) Cyclic Peptides with Anti-Parasitic Activity, , WO2010116985A1;
• Billker, O., Lourido, S., Sibley, L.D., Calcium-dependent signaling and kinases in apicomplexan parasites (2009) Cell Host. Microbe., 5, pp. 612-622
• Ojo, K.K., Larson, E.T., Keyloun, K.R., Toxoplasma gondii calciumdependent protein kinase 1 is a target for selective kinase inhibitors (2010) Nat. Struct. Mol. Biol., 17, pp. 602-607
• Zhang, C., Kenski, D.M., Paulson, J.L., Bonshtien, A., Sessa, G., Cross, J.V., Templeton, D.J., Shokat, K.M., A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases (2005) Nature Methods, 2 (6), pp. 435-441. , DOI 10.1038/nmeth764
• Bishop, A.C., Kung, C.-Y., Shah, K., Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach (1999) J. Am. Chem. Soc., 121, pp. 627-631
• Murphy, R.C., Ojo, K.K., Larson, E.T., Discovery of potent and selective inhibitors of CDPK1 from C parvum and T gondii (2010) ACS Med. Chem. Lett., 1, pp. 331-335
• Johnson, S.M., Murphy, R.C., Geiger, J.A., Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity (2012) J. Med. Chem., , 10.1021/jm201713h
• Van Voorhis, W.C., Hol, W.G.J., Larson, E.T., Composition and methods for treating toxoplasmosis cryptosporidiosis and other apicomplexan protozoan related diseases (2011) WO2011094628A1

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------